Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
Published Online: 2024-09-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alexandra Langlais•Alina Berriolo-Riedinger•Anne Larrouy•Carole Massabeau•Clarisse Audigier-Valette•Cécile Le Péchoux•Céline Berthold•Damien Moreau•Delphine Lerouge•Elodie Amour•Elske Quak•Etienne Giroux-Leprieur•Etienne Martin•Florence Le Tinier•Frédéric Courbon•Gérard Zalcman•Hélène Kolesnikov-Gauthier•Isabelle Brenot-Rossi•Jean Marc Broglia•Khadija Benali•Laurent Tessonnier•Nadia Ghazzar•Naji Salem•Nicolas Pourel•Patricia Moisson•Philippe Chaumet-Riffaud•Philippe Giraud•Pierre Boisselier•Pierre Vera•Pierrick Gouel•Romain Modzelewski•Sophie Guillemard•Sophie Guillerm•Sébastien Hapdey•Sébastien Thureau
